ࡱ> '*$%& bjbj99 !SSl VVDt`|m( , l!l!l!l!l!l!l$pspEl2  22ElHl>>>2l>2l>>-]D%`<7]W8q^& ll0m^t8tL%`%` t+i ~&>*D-@ ElEl=0 m2222t V v:  Pfizer Worldwide Research & DevelopmentChemical R&DEastern Point Rd, MS 8220/2432Groton, CT-06340Tel: (860) 441-3103stephane.caron@pfizer.com Professional Objective Lead as an executive in a scientifically driven organization which enables the discovery, development and commercialization of novel pharmaceutical agents. Develop engaged and talented individuals to achieve their career aspirations.Experience HighlightsProven track record of project delivery at a Large Pharma company in all phases of development with a demonstration of strategic thinking, innovation, operational excellence and strong resource management.Leadership of a large organization and recognized for change agility and ability to develop talent through organizational construct modification. Capability in addressing consumers needs through proven business acumen.Demonstrated leadership in matrix team setting. Led the Chantix Pharmaceutical Sciences Team (1997-2006) and Pharmaceutical Sciences Alliance Manager for a large Pharma collaboration with Merck on ertugliflozin (2012-present).Strong interpersonal skills in cross-functional and multi-disciplinary setting. Member of the Impurity Council which includes Pharmaceutical Sciences, Drug Safety R&D and Pharmacokinetics, Dynamics and Metabolism to review projects and provide guidance around impurity control and qualification. (2003-2016).Proven track record of participating in the planning and implementation of new initiatives. Designed, implemented and managed a new process for Synthesis Management Team in Medicianl Design (2017-present)International scientific track record as shown by Membership of the Inorganic & Organic Chemistry Grant Selection Committee, NSERC. Canada, 2003-2006; Organic Process Research and Development Editorial advisory board, (2007-present); chairing symposia (The Role of Organic Synthesis in Early Clinical Drug Development II, Symposium, 2003 and The Science and Strategy of Process Chemistry: From Molecules to Pharmaceutical Drugs, 2010) and the Asymchem Scientific Advisory Board (2013-present). Served on the Editor Search Committee on one of the most prestigious journal of the American Chemical Society (2016). EducationPh.D., December 1995, University of California at Berkeley. Title of Thesis: "The Synthesis of the Core of the Zaragozic Acids and Squalestatins." Research Advisor: Clayton H. HeathcockM.Sc., March 1991, Universit Laval, Qubec, Canada. Title of Thesis: "Synthse totale de la (dl)-12-hydroxyabita-8,11,13-triene-3,7-dione et approche la synthse de la Candelabrone." Research Advisor: Robert H. BurnellB.Sc., May 1989, Universit Laval, Qubec, Canada.Professional ExperiencePfizer Inc., Pharmaceutical Sciences, Chemical R&D (Aug. 1995-present)Chemical R&DExecutive Director, Jan. 2014-present; Senior Director, Apr. 2010-Dec. 2013; Director, Mar. 2005-Apr. 2010; Associate Director, Nov. 2003-Mar. 2005; Manager, Mar. 2002-Nov. 2003; Project Leader, Aug. 2000-Mar. 2002; Senior Research Scientist, Feb. 1998-Aug. 2000; Research Scientist, Aug. 1995-Feb. 1998.Genentech, Medicinal Chemistry (Apr. 1991-Aug. 1991)Medicinal Chemistry InternResearch and Managerial ExperienceExecutive Director, Chemical Research & Development. (2014-present) - Managed ~60 member chemistry organization supporting the portfolio covering projects from pre-clinical to commercial launch. Supported several managers on strategy for project progression, workforce planning, colleague development and budget. Partnered with Global External Supply group on vendor selection and interactions. Worked in partnership with Worldwide Medicinal Chemistry to support the early development portfolio and with Pfizer Global Supplies for assets approaching commercialization. Senior Director, Chemical Research & Development. (2010-2013) Managed both scientific staff and managers in the late stage development group of CRD. Key point of contact in Co-Development in the introduction of new product to Pfizer Global Supply. Led the effort on outsourcing on development activities within CRD. Participated in several due diligence evaluations as part of business development. Worked in collaboration with partner lines to assess the regulatory application of quality by design (QbD) principles and the interpretation of new guidelines on control of genotoxic impurities. Key member of the Lab of the Future team which led to a major capital project in Pharmaceutical Sciences. Director, Chemical Research & Development. (2005-2010) Transition to the late development group and managed a group of ~20 chemists. Involved in project assessment and transfers following the Pharmacia and Wyeth acquisitions. Led the recruiting team for CRD to talent acquisition. Co-Led the creation of the CRD workflows to standardize project team deliverables and expectations based on project progression. Created the CRD resource prediction template to access overall resource needs and budget for a closed loop resource management system. Led a multi-disciplinary team on developing contemporary practices meeting regulatory expectations for API stability package for new product registration. Project Leader, Process Research. (2000-2002), Manager, Chemical Research & Development. (2002-2003) & Associate Director, Chemical Research & Development.(2003-2005) Increased managerial responsibilities and focus exclusive to early development. Developed the strategy for a much larger portfolio of assets and represented CRD on the Early Development Portfolio Management Team. Started involvement with outsourcing and vendor interactions to mitigate resource constraints. Participated in a number of initiatives to expedite speed of early candidates within Pharmaceutical Sciences. Involved in the organizational design of the department following a merger and the recruitment of employees from research sites that were getting closed. Managed the contracts of the consultants hired by our department. Senior Research Scientist. Process Research (1998-2000) - February 1998-August 2000: Point of contact to the Central Nervous System discovery team (Groton CT) and Pain team (Nagoya, Japan) for introduction on new drug candidates into development. Collaborated with Legal group on patent strategy for new CNS and Pain drug candidates. Supervised two direct reports and enabled chemistry for First in Human studies. Research Scientist. Process Research. (1995-1998) - August 1995-February 1998: supervised one direct report and defined the synthetic strategy of mid-stage drug candidates. Worked in the laboratory and developed technical transfer documentation for scale-up of the chemistry selected. Led the department recruiting effort. AwardsDare to Try Award; Ertugliflozin co-crystal (one of five teams selected across Pfizer in 2016)Pharmaceutical Sciences Pharmatherapeutics Team of the year; ertugliflozin (2014)Pfizer Groton Site Team of the Year Award for Lab of the Future (2010)Top 300 Pfizer Managers based on top 75th percentile in Gallup 12 results (2010)Leader the outstanding Early Clinical Management Team of the year; nicotine partial agonist, (2000). Also received Groton/New London teamwork award (2004) and PGRD team award (2006).Pfizer Fellowship, Department of Chemistry, University of California at Berkeley, (August 1994-July 1995).Fonds FCAR Fellowship, Department of Chemistry, University of California at Berkeley, (August 1991-July 1994).Fonds FCAR Fellowship, Department of Chemistry, Universit Laval, Qubec, (May 1989-January 1991). Appendix: Presentations, Publications and PatentsPresentations:Burnell, R. H., Caron, S. and Girard, M. "Approche de la synthse de la candelabrone." Presented at the 58th ACFAS meeting, Qubec City, Qubec, Canada. May 1990.Caron, S. and Burnell, R. H. "Approche la synthse de la candelabrone." Presented at the 59th ACFAS meeting, Sherbrooke, Qubec, Canada. May 1991.Caron, S. and Heathcock, C. H. "Approach Towards the Synthesis of the core of the Zaragozic acids." Presented at the 208th National Meeting of the ACS, Washington, D.C., August 1994.Caron, S.; Stoermer, D.; Heathcock, C. H. "The Total Synthesis of Zaragozic Acid A/Squalestatin S1." Presented at the Gordon Research Conference on Stereochemistry, Newport, R.I., June 1996.Caron, S. "Directed Ortho Metalation of Neopentyl Benzoates and its Application in the Synthesis of CP-195,543." Presented at the Universit de Montral, Quebec, Canada, May 1998.Caron, S. "Lortho-lithiation des benzoates de nopentyl et son application dans la synthse du CP-195,543." Presented at the 66th ACFAS meeting, Qubec City, Qubec, Canada. May 1998.Caron, S. "Directed Ortho Metalation of Neopentyl Benzoates and its Application in the Synthesis of CP-195,543." Presented at the NSF Workshop on Organic Synthesis and Natural Products Chemistry, Ashland, New Hampshire, July 1998.Caron, S. The Synthesis of CP-195,543. Presented at Cornell University, Ithica, April 1999.Caron, S. The Synthesis of CP-195,543. Presented at the 2nd International Conference on Process Research and Development, New Orleans, April 1999.Caron, S.  Process Research Towards an Efficient Synthesis of a PDE4/TNFa Inhibitor. Presented at the University of California at Berkeley, September 1999.Caron, S.  Process Research Towards an Efficient Synthesis of a PDE4/TNFa Inhibitor. Presented at Organic Reactions and Processes Gordon Research Conference, Bristol RI, July 2000.Caron, S.  Process Research Towards an Efficient Synthesis of NK1 Receptor Antagonist. Presented at 84th CSC meeting, Montreal, May 2001.Caron, S. Process Research Towards an Efficient Synthesis of a NK1 Receptor Antagonist. Presented at Heterocycles Gordon Research Conference, Newport RI, July 2001.Caron, S. Process Research Towards an Efficient Synthesis of a NK1 Receptor Antagonist and a COX-2 Inhibitor. Presented at the IBC and Sepracors Third International Symposium on New Synthetic Methods; Chemistry Advancements for Effective Drug Development, Naples, FL, March 2001.Caron, S. Discovery and Development of Novel Catalysts. 1) Process Research Towards an Enantioselective Synthesis of an NK-1 Antagonist. 2) A New Class of Ligands for the Palladium-Catalyzed Aryl Amination. Presented at the Universit of Montral, Qubec, Canada, November 2002.Caron, S. Introductory Remarks: The Role of Organic Synthesis in Early Clinical Drug Development. 226th ACS National Meeting, New York, September 2003.Caron, S. Academic Industrial Relations, A Changing Landscape. The International conference for New Directions in Chemical Synthesis. Presented at Edinburgh, Scotland, July 2004.Caron, S. Process Research and Development Towards a Selective and Partial GABAA Receptor Inverse Agonist. Presented at the University of Ottawa, Canada, March 2005.Caron, S. Varenicline tartrate: A chemical journey. Presented at the 231st ACS National Meeting, Atlanta, March 2006.Caron, S. The Discovery and Process Development of Varenicline Tartrate: A New Treatment in Smoking Cessation. Presented at the Synthetic Heterocyclic Chemistry Conference (Scientific Update), Barcelona, Spain, April 2007.Caron, S. Process Research and Development of a Factor Xa Inhibitor. Presented at the Stereochemistry Gordon Research Conference, Newport, RI, July 2008.Caron, S. Strategies in Pharmaceutical Development. Presented at the 2010 NSF Workshop on Organic Synthesis and Natural Products Chemistry, Holderness, NH, July 2010.Caron, S. Process Research and Development of Tofacitinib Citrate. Presented at the 3rd Asymchem Pharmaceutical CMC Symposium, Tianjin China, September 2012.Caron, S. Process Research and Development of Tofacitinib Citrate and Applications of Base Metal Catalysis Presented at the University of California at Los Angeles, February 2013.Caron, S. Developing an API Commercial Synthesis; Expectations and Recent Examples Presented at the University of California at San Diego, November 2014.Caron S. Ertugliflozin API Development Presented at Merck, Rahway, October 2015.Caron, S. Developing an API Commercial Synthesis; Expectations and Recent Examples Presented at the University of Rhode Island, October 2015.Caron, S. Relevance of Green Chemistry in Synthetic Methodology and Process Development Presented at the School of Pharmaceutical Science andTechnology Asymchem Green Chemistry Symposium, China, October 2016.Caron, S. Relevance of Green Chemistry in Synthetic Methodology and Process Development Presented at the School of Pharmaceutical Science andTechnology Tianjin University, China, October 2016.Publications:Burnell, R. H.; Caron, S. "Synthesis of Aromatic Diterpenes; Synthesis of 12hydroxyabieta-8,11,13-trien-3,7-dione." Synth. Commun., 1991, 21, 127.Burnell, R. H.; Caron, S. "Approach to the synthesis of candelabrone and synthesis of 3,7-diketo-12-hydroxyabieta-8,11,13-triene." Can. J. Chem. 1992, 70, 1446.Caron, S.; Desfosss, S.; Dionne, R.; Thberge, N.; Burnell, R. H. "Synthesis of Some Minor Quinoline Alkaloids Found in Galipea Longiflora." J. Nat. Prod. 1993, 56, 138.Caron, S.; McDonald, A. I.; Heathcock, C. H. "Synthesis of 1-Substituted and 1,4Disubstituted 2,3-Di-O-benzyl-1,6-anhydrogalactofuranoses." J. Org. Chem., 1995, 60, 2780.Caron, S.; McDonald, A. I.; Heathcock, C. H. "An Improved Synthesis of 1,6-Anhydro-2,3-di-O-benzyl-b-D0xylo-hexopyranos-4-ulose." Carb. Res., 1996, 281, 179.Stoermer, D.; Caron, S.; Heathcock, C. H. "Total Synthesis of Zaragozic Acid A (Squalestatin S1). Degradation to a Relay Compound and Reassembly of the Natural Product." J. Org. Chem., 1996, 61, 9115.Caron, S.; Stoermer, D.; Mapp, A. K.; Heathcock, C. H. "Total Synthesis of Zaragozic Acid A (Squalestatin S1). Synthesis of the Relay Compound." J. Org. Chem., 1996, 61, 9126.Caron, S.; Hawkins, J. M. "Directed Ortho Metalation of Neopentyl Benzoates with LDA: Preparation of Arylboronic Acids." J. Org. Chem., 1998, 63, 2054.Caron, S.; Vazquez, E. A Versatile and Efficient Synthesis of Substituted 1H-Indazoles. Synthesis, 1999, 588.Caron, S. The Synthesis of CP-195,543, an LTB4 Antagonist for the Treatment of Inflammatory Diseases. Curr. Opin. Drug Discovery Dev., 1999, 2, 550.Caron, S.; Vazquez, E.; Wojcik, J. M. Preparation of Tertiary Benzylic Nitriles from Aryl Fluorides. J. Am. Chem. Soc., 2000, 122, 712.Caron, S.; Do, N. M.; Sieser, J. E. A Practical, Efficient, and Rapid Method for the Oxidation of Electron Deficient Pyridines Using Trifluoroacetic Anhydride and Hydrogen Peroxide-Urea Complex. Tetrahedron Lett., 2000, 41, 2299.Caron, S.; Massett, S. S.; Bogle, D. E.; Castaldi, M. J.; Braish, T. F. An Efficient and Cost-Effective Synthesis of 2-Phenyl-3-aminopyridine. Org. Process Res. Dev., 2001, 5, 254.Caron, S.; Vazquez, E. The Synthesis of a Selective PDE4/TNFa Inhibitor. Org. Process Res. Dev., 2001, 5, 587. Caron, S.; Wojcik, J. M.; Vazquez, E.  Nucleophilic Aromatic Substitution of Aryl Fluorides by Secondary Nitriles: Preparation of 2-(2-Methoxyphenyl)-2-methylpropionitirle. Org. Syn. 2002, 79, 209. Ghosh, A.; Sieser, J. E.; Caron, S.; Watson, T. J. N. Synthesis of the kappa-agonist CJ-15,161 via a palladium-catalyzed cross-coupling reaction. Chem. Commun. 2002, 1644.Caron, S.; VazquezHYPERLINK "http://pubs.acs.org/cgi-bin/article.cgi/joceah/2003/68/i10/html/" \l "jo034274rAF2", E.; Stevens, R. W.; Nakao, K.; Koike, H.; Murata Y. Efficient Synthesis of [6-Chloro-2-(4-chlorobenzoyl)-1H-indol-3-yl]-acetic Acid, a Novel COX-2 Inhibitor. J. Org. Chem. 2003, 68, 4104.Caron, S.; Do, N. M.; Arpin, P.; Larive, A. Enantioselective Addition of a Trifluoromethyl Anion to Aryl Ketones and Aldehydes. Synthesis, 2003, 1693.Singer, R. A.; Caron, S.; McDermott, R. E.; Arpin, P.; Do, N. M. Alternative Biarlyphosphines for Use in the Palladium-Catalyzed Amination of Aryl Halides. Synthesis, 2003, 1727.Caron, S.; Do, N. M. Generation of Bromophenyllithium Reagents from Dibromobenzenes and Addition to Carbonyl and Nitrile electrophiles. Synlett, 2004, 1440.Brooks, P. R.; Caron, S.; Coe, j. W.; Ng, K. K.; singer, R. A.; Vazquez, E.; Vetelino, M. G.; Watson, Jr., H. H.; Whritenour, D. C.; Wirtz, M. C. Synthesis of 2,3,4,5-Tetrahydro-1,5-methano-1H-3-benzazepine via Oxidative Cleavage and Reductive Amination Strategies. Synthesis, 2004, 1755.Ghosh, Arun; Sieser, Janice E.; Caron, Stephane; Couturier, Michel; Dupont-Gaudet, Kristina; Girardin, Melina. Cu-Catalyzed N-Arylation of Oxazolidinones: An Efficient Synthesis of the d-Opioid Receptor Agonist CJ-15161. J. Org. Chem. 2006, 71, 1258. Caron, Stphane; Do Nga M.; McDermott,Ruth E.; S. Bahmanyar  Regioselective Synthesis of an Imidazo[4,5-c]pyridine through Selective Acylation of 3,4-Diaminopyridine: Synthesis of CP-885,316. Org. Process Res. Dev. 2006, 10, 257. Dobo, Krista L.; Greene, Nigel; Cyr, Michelle O.; Caron, Stphane; Ku, Warren W. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development. Regulatory Toxicology and Pharmacology, 2006, 44, 282.Caron, Stephane; Dugger, Robert W.; Ruggeri, Sally Gut; Ragan, John A.; Ripin, David H. Brown. Large-Scale Oxidations in the Pharmaceutical Industry. Chem. Rev. 2006, 106, 2943.Andresen, Brian M.; Caron, Stphane; Couturier, Michel; DeVries, Keith M.; Do, Nga M.; Dupont-Gaudet, Kristina; Ghosh, Arun; Girardin, Melina; Hawkins, Joel M.; Makowski, Teresa M.; Riou, Maxime; Sieser, Janice E.; Tucker, John L.; Vanderplas, Brian C.; Watson, Timothy J. N. Process research and scale-up of the k-opioid receptor agonist CJ-15,161 drug candidate. Chimia, 2006, 60, 554.Caron, Stphane; Do, Nga M.; Sieser, Janice E.; Arpin, Patrice; Vazquez, Enrique. Process Research and Development of an NK-1 Receptor Antagonist.  Enantioselective Trifluoromethyl Addition to a Ketone in the Preparation of a Chiral Isochroman. Org. Process Res. Dev. 2007, 11, 1015-1024.Brandt, Thomas A.; Caron, Stphane; Damon, David B.; DiBrino,Joseph; Ghosh, Arun; Griffith, David A.; Kedia, Sandeep; Ragan, John A.; Rose, Peter R.; Vanderplas, Brian C.; Wei, Lulin. HYPERLINK "http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6THR-4TS6SGY-D&_user=5844500&_coverDate=10%2F25%2F2008&_alid=853861992&_rdoc=1&_fmt=high&_orig=search&_cdi=5289&_sort=d&_docanchor=&view=c&_ct=10&_acct=C000000313&_version=1&_urlVersion=0&_userid=5844500&md5=ed6ffc8e92bd64b214363e6f4063f6d6"Development of two synthetic routes to CE-178,253, a CB1 antagonist for the treatment of obesity. Tetrahedron, 2009, 65, 3292.Caron, Stphane; Do, Nga M.; Sieser, Janice E.; Whritenour, David C.; Hill, Paul D. Preparation of a Corticotropin-Releasing Factor Antagonist by Nucleophilic Aromatic Substitution and Copper-Mediated Ether Formation. Org. Process Res. Dev. 2009, 13, 324.CaronHYPERLINK "http://pubs.acs.org/doi/full/10.1021/jo902159z" \l "cor1", Stphane; Wei, Lulin;Douville, Jasmin; Ghosh, Arun.Preparation and Utility of Trihaloethyl Imidates: Useful Reagents for the Synthesis of Amidines J. Org. Chem., 2010, 75, 945947.Lafrance, Danny G.; Caron, Stphane. New Synthetic Route to PF-734200. Org. Process Res. Dev. 2012, 16, 409-414.Brenek, Steven; Caron, Stphane; Chisowa, Esmort; Colon-Cruz, Roberto; Delude,Mark P.; Drexler, Michele T.; Handfield, Robert E.; Jones, Brian P.; Nadkarni, Durgesh; Nelson, Jade D.; Olivier, Mark; Weekly, R. Matt; Bellinger, G. C. A.; Brkic, Zinka; Choi, Neil; Desneves, Joe; Lee, Maria A.-P.; Pearce, Wayne; Watson, Jessica K.. HYPERLINK "http://pubs.acs.org/doi/abs/10.1021/op300130p"Development of a Second-Generation Process to Antibacterial Candidate Sulopenem. Org. Process Res. Dev. 2012, 16, 1338-1347..Brenek, Steven; Caron, Stphane; Chisowa, Esmort; Delude, Mark P.; Drexler, Michele T.; Handfield, Robert E.; Ide, Nathan D.; Nadkarni, Durgesh; Nelson, Jade D.; Olivier, Mark; Perfect, Hahdi; Phillips, James E.; Teixeira, John J. R.; Weekly, R. Matt; Zelina, John P. HYPERLINK "http://pubs.acs.org/doi/abs/10.1021/op300131e"Development of a Practical and Convergent Process for the Preparation of Sulopenem. Org. Process Res. Dev. 2012, 16, 1348-1359.Caron, Stphane; Jones, Brian P.; Wei, Lulin. Preparation of Substituted-Benzimidazoles and Imidazopyridines Using 2,2,2-Trichloroethyl Imidates. Synthesis, 2012, 44, 3049-3054.Caron, Stphane; Jones, Brian P.; Wei, Lulin.  HYPERLINK "javascript:goFormView(%22/OrgSyn/orgsyn/orgsyn_form.asp?formgroup=quick_form_group&dbname=orgsyn&formmode=edit&unique_id=undefined&commit_type=undefined%22,%2217%22)" Preparation of N1-Phenylacetamidine 4-Bromobenzoate Using 2,2,2-Trichloroethyl Acetimidate Hydrochloride.Org. Syn.. 2013, 90, 174-181.Bowles, Paul; Brenek, Steven J.; Caron, Stphane; Do, Nga M.; Drexler, Michele T.; Duan, Shengquan; Dube, Pascal; Hansen, Eric C.; Jones, Brian P.; Jones, Kris N.; et al;  HYPERLINK "https://scifinder.cas.org/scifinder/references/answers/D4FC6602X86F350ACX1EB2234131CE9C7DF7:D4FCF6EDX86F350ACX25691B7A1765EC6331/1.html?nav=eNpdkM8vA0EUx59tRIQDLiJCHByEZFZVt6QSqj9obLbSIuIio53UsruznZlWexEOOLg4KBcHBzfuxJ8gcRQuEnHnKnEy2xJhTi_v-51Pvu979QaNAhqwgP7YaCKa0OKx5TEtEQgOR6LLI0Ft3D8divhDWjAe1QIBv7SucQbtG7iEkYWdPEo6guQJ63g9v_jYPRhToCEJjSVsFUmZQduvzyjaa4TtX1V7Wo5fDhWAsgsAPglcF9AdWVyYTaVXk8ZS3FiQg5FanUmnFueTxoyAZtN2KROSwAuwDT75D-R203bTpPBvqzD6N980pRbBzn0f23k4-3yX-VZ-8rmen3PpH6Isj7KYI8qzmCFOWIkwlKM2Nh2UpbZNHZSRETIuyU4cXZ73nL7cKaDo0GpXUixnOtiaIxUBA7oEqRKk1kBqHaTWQWodpEpnWIcmu-IRuYAu3UurFoVpqbrpbJLcLObrGSLCZdeV4Tprx3gy-iM_WY8r1efBXq_Ln5Nrrm_9NrZXPbm5HvV5XW-1ynraJqeg9spfuEejiA&key=caplus_2013:1974382&title=Q29tbWVyY2lhbCBSb3V0ZSBSZXNlYXJjaCBhbmQgRGV2ZWxvcG1lbnQgZm9yIFNHTFQyIEluaGliaXRvciBDYW5kaWRhdGUgRXJ0dWdsaWZsb3ppbg&launchSrc=reflist&pageNum=1&sortKey=ACCESSION_NUMBER&sortOrder=DESCENDING" Commercial Route Research and Development for SGLT2 Inhibitor Candidate Ertugliflozin Org. Process Res, Dev.2014,18,66-81.Caron, Stphane; Thomson, Nicholas  HYPERLINK "http://pubs.acs.org.proxy1.athensams.net/doi/abs/10.1021/jo502879m" Pharmaceutical Process Chemistry: Evolution of a Contemporary Data-Rich Laboratory Environment. J. Org. Chem. 2015, 80, 2943-2958.Hansen, Eric; Pedro, Dylan; Wotal, Alexander; Gower, Nicholas; Nelson, Jade; Caron, Stphane; Weix, Daniel "New Ligands for Nickel Catalysis from Diverse Pharmaceutical Heterocycle Libraries" Nature Chem., 2016, 8, 1126-1130.Wang, Ke; Liu, Fangfang; Caron, Stphane Caron; Vukovinsky Kimberly E. Distribution Quantification of Synthetic Amino Acid Oligomers Pharm. Eng. 2016, 36(6), 81-85.Book or Book Chapter:"Fundamentals of Early Clinical Drug Development; From Synthesis Design to Formulation." Ahmed F. Abdel-Magid & Stphane Caron, Editors. Wiley-Interscience, 2006.Responsibilities of the Process Chemist: Beyond Synthetic Organic Chemistry. Chapter #7 in "Fundamentals of Early Clinical Drug Development; From Synthesis Design to Formulation." Ahmed F. Abdel-Magid & Stphane Caron, Editors. Wiley-Interscience, 2006.Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Nucleophilic Aromatic Substitution. Chapter #4 with Arun Ghosh in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Electrophilic Aromatic Substitution. Chapter #5 with in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Selected Metal-Mediated Cross-Coupling Reactions. Chapter #6 with Arun Ghosh, Sally Gut Ruggeri, Nathan D. Ide, Jade D. Nelson and John A. Ragan in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Reductions. Chapter #8 with Sally Gut Ruggeri, Pascal Dub, Nathan D. Ide, Kristin E. Price, John A. Ragan and Shu Yu in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Synthesis of Common Aromatic Heterocycles. Chapter #13 in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Synthetic Route Development of Selected Contemporary Pharmaceutical Drugs. Chapter #15 in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.General Solvent Properties. Chapter #19 in Practical Synthetic Organic Chemistry: Reactions, Principles, and Techniques. Stphane Caron Editor. Wiley, 2011.Granted Patents:Methods of Preparing 4-Cyano-4-(Substituted Indazole) Cyclohexane Carboxylic Acids Useful as PDE4 Inhibitors. Caron, S.; U. S. 6005118, 12/21/1999.Processes and Intermediates for Preparing Substituted Indazole Derivatives. Caron, S.; Eisenbeis, S. A. U. S. 6011159, 1/4/2000. Processes for preparing substituted chromanol derivatives. Piscopio, A.; Hawkins, J. M.; Caron, S.; Kelly, S. E.; Raggon, J. W.; Castaldi, M. J.; Dugger, R. W.; Ruggeri, S. G.; U. S. 6096906, 8/1/2000.Processes and intermediates for preparing substituted chromanol derivatives. Piscopio, A.; Hawkins, J. M.; Caron, S.; Kelly, S. E.; Raggon, J. W.; Castaldi, M. J.; Dugger, R. W.; Ruggeri, S. G.; U.S. 6288242, 9/11/2001.Process for preparing benzylnitriles. Caron, S.; U.S. 6303782, 10/16/2001.Process for preparing 2-phenyl-3-aminopyridine, substituted phenyl derivatives, thereof, and salt thereof. Caron, S.; U.S. 6316632, 11/13/2001. Processes and intermediates for preparing substituted chromanol derivatives. Piscopio, A.; Hawkins, J. M.; Caron, S.; Kelly, S. E.; Raggon, J. W.; Castaldi, M. J.; Dugger, R. W.; Ruggeri, S. G.; U.S. 6355825, 3/12/2002. Processes and intermediates for preparing substituted chromanol derivatives. Piscopio, A.; Hawkins, J. M.; Caron, S.; Kelly, S. E.; Raggon, J. W.; Castaldi, M. J.; Dugger, R. W.; Ruggeri, S. G.; U.S. 6444826, 9/3/2002.Process for the preparation )67{   0 9 O P A M 乫ڡxgxgV!hx:hxEB*CJOJQJph!hx:htB*CJOJQJph!hx:h)B*CJOJQJphhRLh`>*CJOJQJh\g"CJOJQJhCJOJQJhRLhJ\>*CJOJQJhmCJOJQJmH sH $hmhm>*B*CJOJQJph5:hs^CJOJQJhJ\CJOJQJhmCJOJQJh1wOJQJ!*7Vg{ hdgdmh hdh  h  h ^gdm hl^gdm  hlgdm  hlh b F |JS|} h$ ^$ `h0^`0gd` hgd`hgd`hh^hgd) & Fhh^hgd) & Fhh^hgdt hd     J P b  $ 5 D F uy{|IJ|̾ݾݭtcREh)h)CJOJQJ!hNwh)B*CJOJQJph!hNwh#qB*CJOJQJph!hNwhNwB*CJOJQJph!h#qhxEB*CJOJQJphh#qCJOJQJh)hxECJOJQJ!h)h)B*CJOJQJphh#qB*CJOJQJph!hx:h)B*CJOJQJph!hx:hxEB*CJOJQJph!hx:htB*CJOJQJph 7 Te}8:K´{iXJ8#h)hJ\6CJOJQJmH sH h`CJOJQJmH sH  h[ThJ\CJOJQJmH sH #h[ThJ\6CJOJQJmH sH hFlhJ\CJOJQJhFlh5pCJOJQJhJ\6CJOJQJh5pCJOJQJhJ\CJOJQJhRLhJ\>*CJOJQJ h`hRL!hx:hxEB*CJOJQJphhCJOJQJh)h)CJOJQJh)h)6CJOJQJ}_`1fn hgd9<h  hgdRLgdRL hd h0^`0gd)h0^`0gd) hgd)K`b&'LM1:<OQdfzͿ}}rrh}ZLBhJ\CJOJQJhBhJ\>*CJOJQJhBhB>*CJOJQJhE\CJOJQJhRL5CJOJQJhRLhRLCJOJQJhRLCJOJQJhRLhRL56CJOJQJhRL56CJOJQJhRLhRL5CJOJQJhRLhRL>*CJOJQJ hRLhJ\CJOJQJmH sH hRLh5pCJOJQJmH sH h)hJ\CJOJQJmH sH 34>I"$%&ɿɿɿɿɿɵɫɿyyoeWhMhM5CJOJQJhCJOJQJh VCJOJQJhiCJOJQJh;1h;156CJOJQJh;1h;15CJOJQJhtsCJOJQJh.CJOJQJheCJOJQJh;1CJOJQJhaCJOJQJh;1h9<56CJOJQJh;1h9<5CJOJQJh;1hts5CJOJQJ$mopɿɿ㗍oaVHhMhG)t5CJOJQJhG)t5CJOJQJhG)thG)t5CJOJQJhMhm~56CJOJQJhMhm~5CJOJQJhm~CJOJQJhG)tCJOJQJhJ\CJOJQJh VCJOJQJhRCJOJQJhiCJOJQJhMCJOJQJhMhM56CJOJQJhMhM5CJOJQJhMh5CJOJQJnpF!I!"""""""M#N#####$$ % % hgdxE hgdgddh h8^8` hgd9<PQS[ E!F!I!q!z!{!~!!!"""ĺذΰ~tgtΰ~]haCJOJQJh4Kh4KCJOJQJh4KCJOJQJhoCJOJQJhMhM56CJOJQJhMhM5CJOJQJh VCJOJQJhJ\CJOJQJh` CJOJQJhG)tCJOJQJhMCJOJQJhm~CJOJQJhMhG)t5CJOJQJhMhG)t56CJOJQJ$"""""N####L$M$$$%%%&&&%&&&~&&'c'ǽǯǢǎtdYHH h[ThJ\CJOJQJmH sH hJ\5CJOJQJhthJ\5>*CJOJQJhtht5>*CJOJQJha3CJOJQJhJ\CJOJQJhxECJOJQJhxEhxECJOJQJhhCJH*OJQJhtCJOJQJhCJOJQJhzuVCJOJQJ hJ\CJh)hJ\5>*CJOJQJh)hJ\>*CJOJQJ %{%|%%%&&&%&&&&&c'd'(((())O* hgdqhL^`Lgdq  & Fhgdq  hgdhL^`L hgdc')**+++,,,,,...6.8.///1C2D223^3{5b6c67787zpf\V hCJh&+CJOJQJhR?{CJOJQJhYCJOJQJhOc#CJOJQJ^Jh6<;B*CJOJQJ^JphhOc#B*CJOJQJ^JphhOc#CJH*OJQJhOc#CJOJQJhCJOJQJhCJH*OJQJhCJH*OJQJhCJOJQJ h[ThCJOJQJmH sH hCJOJQJO*P*8+9+++b,d,--//0000112233R4S444{5|5  & Fhgdq hgdq|5b6c67777P8Q8999999::_;`;%<&<  hgdqhh^hgd'gd'  & Fhgd'gdzgdq hgdq  & Fhgdq8797778 8O8P8Q8{88888888999999=9[9\9f9n999zmcVcLmcmh.CJOJQJh-h-CJOJQJh-CJOJQJhwgh-CJOJQJ h-CJhwgh.CJOJQJhthtCJOJQJhtCJOJQJhs^CJOJQJhwghtCJOJQJ htCJhYCJOJQJhwghwgCJH*OJQJhwghwgCJOJQJ hwgCJhCJOJQJhwgCJOJQJ9999999::.:M:_:y:{:::::&;H;];^;_;`;;#<$<%<'<5<U<ƼƼƼƥ{ndYdhJ\5CJOJQJhJ\CJOJQJh'hqCJOJQJh'h)qCJOJQJh6:CJOJQJh'h'CJOJQJ h'CJh'CJOJQJh-hqCJOJQJhqCJOJQJhwghqCJOJQJ hqCJhzCJOJQJ hzCJhwgh-CJOJQJh-CJOJQJ&<'<5<6<<<o=p=>>>>k?l?8@9@@@AAAAB hgdq & Fhh^hgdq hhL^h`L hL^`LU<t<<<<<<<<P=]=_=c=e=g=p====>>>>>>>>>>>>>>&?'?3?7?O?Y?Z?_?a?d?@&@(@,@.@0@7@8@@@@@@@@@iAvAxA|A~AAḀ̶̶̶̶̶̶̶ h[ThOc#CJOJQJmH sH hOc#5CJOJQJhOc#6CJOJQJhOc#CJOJQJhJ\5CJOJQJhJ\6CJOJQJhJ\CJOJQJh6<;CJOJQJAAAAAAAAA)B*BdBBBBBBCCCC CECCCCCDD DDDDDDDDDFFFHFLFTFVFXFZFjFlFFGG꼳꼖hR?{hOc#CJhmH sH hOc#CJ\hhOc#CJOJQJhhOc#OJQJhhOc#5CJhhOc#6CJhhOc#CJh hR?{hOc#CJOJQJmH sH hOc#CJH*OJQJhOc#5CJOJQJhOc#CJOJQJhOc#6CJOJQJ2BBC C D DDDjFlFHHHHIIJJ:K;KKKMMN & Fh^hgdq & Fhh^hgdq hgdqGGGGGHHHHHHHHHHH"I#I$I%I\IIIIIIIIIIkJtJvJzJJJ#K,K.K2K:Kɾɳѭ|rhrhhOc#5CJ\hhOc#6CJ]hhOc#5CJ\hOc#6CJ]hOc#6CJ]aJ$hOc#CJaJ$h+jh+U hOc#CJhOc#5CJ\^JhOc#6CJ]^JhOc#CJ^JhOc#CJOJQJhOc#CJhhOc#6CJhhOc#CJ]hhOc#5CJ\]h(:K;KKKKKKKLLLLLLLMMNNPNhNlNtNxN|NNNNPP P$P&P)P/P0P1PP>QeQfQjQlQnQpQtQuQRʙʐʙʄyhoh,=TCJaJ h,=TCJ hMCJhOc#5CJ\hOc#6CJ]h[ThOc#CJmHsHhOc#5CJhh6CJhhOc#6CJh hOc#CJhOc#CJOJQJhhOc#5CJ\hhOc#6CJ]hhOc#CJhhOc#CJOJQJ/NN0P1PuQvQ/R0RTTrVsVXXYYZZk[l[r]s]t]>_?_@_gdqgdq & Fh^hgdq hgdqRRR"R#R$R'R-R.R/R0RNRFSGSTTdTfThTlTxT|TTTTTTΩsjajUIUhh5CJaJhh6CJaJha36CJaJh6CJaJhhCJOJQJaJha3CJaJhhCJaJhCJaJhCJOJQJaJhhCJOJQJaJhF_CJaJhF_ho6CJ\aJhohoCJaJhF_hF_5CJ]aJhF_6CJ]aJhoho6CJ]aJTTTT@UUUCVDVEVWV[V\V`VcVeVgVpVø~l[I;[h-@CJOJQJ^JaJ#h-@h-@6CJOJQJ^JaJ h-@h-@CJOJQJ^JaJ#h-@h-@5CJOJQJ^JaJh-@6CJOJQJaJh"h-@h-@6CJOJQJaJhh-@6CJhh-@CJaJhR?{CJaJha3h-@CJaJhR?{h-@CJaJmH sH $hR?{h-@CJOJQJaJmH sH h-@CJOJQJaJh-@h-@CJOJQJaJpVqVrVsVVVVVVVVVVVVVVVVVVVVVVVVVVVVVWWWWWW"W#W)W,W-WcXdXXXXXXXXXXļ̬̼Ġ̗hMCJaJhM5CJaJhR?{hR?{6CJaJhMhR?{CJH*aJh+jh+UhR?{CJaJhR?{hR?{CJaJhR?{CJOJQJaJhR?{ha3CJOJQJaJhR?{CJOJQJ^JaJ5XXXXXXX_喊~vhFlCJaJhh5CJaJhh6CJaJhhCJaJhBxhCJaJhT0CJaJhBxh6CJaJh5CJaJhR?{h6CJaJhFlh6CJaJh+jh+UhCJaJhFlhCJaJ.>_?_@_n____________$`%`&```BaCaDaEaFaOaQaƼvk\\TL\CLh6CJaJhCJaJhCJaJjhhCJUaJhhCJaJhhCJaJmH sH hhCJaJhhCJaJhe/CJhhe/6CJhh5CJ\hhCJhh6CJ]hhh6CJ]hhhCJaJhhCJaJmH sH hT0CJaJhhT0CJaJ@___daea&f'f"g#ghhhhhhh hh^h`gd'wg hL^`Lgd'wg 7$8$H$gd & Fh7$8$H$^hgdgd & Fh^hgdgdgdqgdq & Fh^hgdqQaUaWaYadaeapaabbbeeeeefffffffff%f&f'fKfLfffffffȻԻԻȴȠȅzqdqdqdqjh.h.CJUh.h.CJh.h"CJaJh"htsCJaJh!htsCJhts5CJh!hts5CJhr'hts6CJhts6CJjhr'htsCJU htsCJ hCJhr'htsCJhtsCJaJh6CJaJhCJaJh5CJaJ#fgggg!g"g#ggggggghhhhhhhh$h%h&h6h@hAhKhLhMhNhhhhhhhhhhhhhƽ|v h'wgCJh5CJhh6CJhhCJ hCJhz6CJ hzCJhj1h5CJhj1h6CJhj1hCJ hCJ h8CJh"h"CJh"6CJh.h.CJh.h.5CJh.h.6CJ+hhdihijikifjjjljmjnjjjjjjk"k&k'kskkkkkkkkkkk"lClGlIlJlKlSlTlqlrllll-mNmRmTmUmVmWmammmmmmn?nCnDnEnFnGnpn|nnnֵֻֻֻֻֻh.h.CJOJQJ h.CJh2{h2{5CJOJQJh2{h2{CJOJQJh2{CJOJQJh.CJOJQJh'wgCJOJQJh'wg5CJOJQJBhjikiljmjjjkkIlJlTmUmVmEnFnnnoofpgphp  hdhh^h`gd'wggdq hgdq & Fhh^hgdqnnnnnnn@oLoOooooooooooo?p`pcpepfpgphpypzpppqqv&'(ööݶsqk h^BCJUhRhRCJOJQJhRhJ\CJH*OJQJ hRhJ\hRhJ\CJOJQJhJ\CJOJQJh'wgCJOJQJh2{h2{CJOJQJh2{h.CJOJQJh.h2{CJOJQJh2{5CJOJQJh2{h2{5CJOJQJh2{CJOJQJ%hpypzpqqqqdrerCsDsss%t&tuuuuuv'  hgdq & Fgdq hgdqhgdq  & Fhgdq  hd of piperidinylaminomethyl trifluoromethyl cyclic ether compounds Caron, S.; Vasquez, E.; U.S. 6486325, 11/26/2002.2,3-Substituted indole compounds as anti-inflammatory and analgesic agents Nakao, K.; Stevens, R. W.; Kawamura, K.; Uchida, C.; Koike, H.; Caron, S.; U.S. 6608070, 8/19/2003.Optically active 3-[(2-Piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT 1D receptor selective antagonists. Howard, H. R. Jr; Adam, M.; Caron, S.; EP 1113015, 9/15/2004.Processes for preparing substituted aryl boronic acids  HYPERLINK "http://www.micropat.com/perl/di/psrecord.pl?ticket=302269348856&listid=84128200606011547&container_id=323345&patnum=US7045652B2" \l "hit3#hit3" Caron, S.; Nowakowski, J.; U.S. 7045652, 5/16/2006.Process for preparing haloalkyl pyrimidines Singer, R. A.; McDermott, R. E ; Do, N. M.; Caron, S.; EP1549649 B1, 7/26/2006.Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction Ghosh, A.; Caron, S.; Sieser, J. E.; U.S. 7223870, 5/29/2007."Benzyl(idene)-lactam derivatives Tao, Y.; Raggon, J. W.; Do, N. M.; Brodney, M. A.; Helal, C. J.; Caron, S.; U.S. 7479449, 1/20/2009. Methods for preparing SGLT2 inhibitors Brenek, S. J.; Caron, S.; Nelson, J. D. HYPERLINK "https://patents.justia.com/inventor/jade-d-nelson" ; Webster, M. E.; Weekly, R. M.; US 9,573,959, 2/21/2017.Stphane Caron Ph.D.  INCLUDEPICTURE "https://www.bosulif.com/sites/default/themes/danland/images/logo_mob.png" \* MERGEFORMATINET    INCLUDEPICTURE "http://www.ibrance.com/sites/default/themes/palbo/logo.png" \* MERGEFORMATINET    '( () hgdmgd+*%gdq & Fgdq  hgdq & Fgdqgdq(67 &'(*+ӲөөӠ|vmvgvZjh+*%h+*%CJU h9CCJh+*%h+*%CJ h+*%CJh\Bh\BCJ h^BCJ haCJ h\BCJhRhaCJhRhCJhRhhMCJ'hRhtF5B*OJQJ\^JphjhRh+CJUhRhtFCJhRhtFCJOJQJh^BCJOJQJhRh^BCJOJQJ#CDEFfi}|}~ø~zezXj*hB*Uph)jhE\hB*UmHnHphuhTjhB*UphhE\B*phjhE\B*UphhE\hahmha6OJQJmH sH hmhamH sH (hmhmCJ$OJQJ^JaJ$mH sH hKijhKiU h+*%CJjh+*%h+*%CJUh+*%h+*%CJ" & Fgdq($P]P^a$gd( !&į h+*%CJhKih:hE\)jhE\hB*UmHnHphuhB*mHnHphu)j$chhB*UmHnHphu)j3DhE\hB*UmHnHphuhT B00P1h:pm/ =!"#$% DpI 000P1h:pm/ =!"#$% P DpI 000P1h:pm/ =!"#$% P DpE 000P1h:pT/ =!"#$% DpDdn  s A<logo_mobirc_miyK yK https://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjxgvHTmqDLAhWLWj4KHbWeB2UQjRwIBw&url=https%3A%2F%2Fwww.bosulif.com%2F&bvm=bv.115339255,d.cWw&psig=AFQjCNE529cWN00tyIDnjvufSuHLOn1izQ&ust=1456946456785832yX;H,]ą'c"`bx1WƼ1 Dsn}x1WƼ1 PNG  IHDRCgytEXtSoftwareAdobe ImageReadyqe< iTXtXML:com.adobe.xmp zIDATx]Kn<f[ ZYf l 60@/f}$Y b f`'aIŸB"%KӖů^,XEz߇?}:BSr.ϊK#G_*2_TE@(@}?^A /w^#r%-ڄsnYԑg p>B;(i7e9W+ v"ؕ#Ïfb]r}I:)qoO?8}\ɠZp ITQv KE^n.S_(}n>Ө?$omg1y"WC+V9רk(3L9_}zs[/ACk B*-52 G(;9A`ްfSbCM ;8R) *gSmOÎE {emz 'h[5*%^C'1U)ehw~a(OqGTnw~Fuw{D1$)lLĬ׺rI!A4‚!_$hH2oSH]hvUN,d⿬N ԗm/0s ,h!hG{S{Ū{C U@su.UJ9vQh+a`+?I.\kھb;@g!Y<}~Ƽ-5i؞gEalC1͕߇n vlKmS3+l5ߢ E۹vԿf%oѯe]Ll}i9>t&Dงl(h@fV|AI e7$4;p <4`y 8})R䉴 *m9g-X^rΡ6GG'\Ȟف^D>T1Go۵tejQ?*'F>p䓿vwkײo\ }!B Sfc8@Y&OĿ&U2LK94O Sn] KiRMOI ݤ%;TtLvgnkV-X&8BVMV%Hw_TT6\+^tc(zmm\F%hP_`Iэѡ]X8Z0ޜ&ڦHrڴ9CϖNŭNΉcPȦ2O-@Nm;U4S}Su# !J$U3_?IŕrD&[d}W=33e 4eL#C)BUש-rI@uS +#`'Lay,_$.6mjQK5I&==S< 찏,#;2v ʎe}ڢR5b27k&C%/k8eP}8aN1(nKH$bo\j&]M@` .6}b0]*D2+ӫ>ʥr4g6@UL*tS|N0;%Ȫ3o9[$`4!IGS~~Yc&*|^2sÐ|WA/_$;f׋NrX|5>2LC[&h7-V} D3~ŗ+@M׷lwϾ(wU>՚2e |P $߯Z̚>bͥk\6>dXTN0)KXa}}m+%q$'(p!ouCIbꇧfqPr KQ0Y9 mWP%eb1f} plcC 8(AƾkCmE(Y1 :劽\Y۞Z*aH{A#<Ȩ5` 6>zk!ۇ=\Obm'Mɥ_YM]D:gyNZ 5N-R/Ig/Jk4ўMڈ9b5Tf;`۴B|4b4Ħ,3#w̶YQOWb` c`L5!^S"N?$|^QD -Ёӑv`JiF&}#aBY!= _I"d)/ .d R 8hZnPHZz ]r#dfFGcNlg;(q.-;8Q{#ram0`=itP(9aߤ1}B݄)T6e۸r7`YpLL_6 H5p:=hm"L%pR oky!rJH֛~/ZφSπ kPiQ"'agBź ׻F rଏRvߩXڨ@ޞђJvpR7-=%OHz^'yE !GZ6h&lSW7's~mζZ^eJUa8׵1I"=0qfr( 0'M0J\v^H:6msC]V;xN\p2K.=_ cNn.}`wy8k03|>,vMu.wXen A(D[T<`V*Y}2+ɱuUx@gs ! vPK9rP`o֟kψOɘμrэh!:x&}ίw8gDE貺0$B)'ݫ;|iA\c'9Վ .1 ǐ' `#`t("4IB䔔vN{!yس1iBjm拓%sTO)_v&uS?m36XA8TmyVg&mP*L߿%F5B=SN,[X&A" gXGj6e{x}8rԕlE0-Ӂ4*Q>M;ՌAmERR߈}PlQ- GT_=ɣ p!<oepI4yXjU_,"۴|:a%]VųhgqK ECG0Y!#=_!%'ラ\Y{aOTUv&I_r6XA;b{n,!z&U P3 1:gIa=Y!mwyk D`}La"|/TNrV%TJ*fko1r+7 Pi LvPKx`rTv?T #xרď:*Fh_L#(*qg Q5Nȸ\bۭ]+)cCE)2G 0Ѧ('IENDB`Dd9OT  PA ?ÐV chantix-logo(2)irc_mihttp://www.mainepersonalinjurylaw.com/uploads/image/chantix-logo(2).jpgyK yK *http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjz5saemaDLAhXEVT4KHWnWCWkQjRwIBw&url=http://www.mainepersonalinjurylaw.com/2011/07/&bvm=bv.115339255,d.cWw&psig=AFQjCNH5y8MuyGY5DSgpyUM62atXUsFogg&ust=1456946060398627yX;H,]ą'c#" `R8/.dm;sF8/.dm;JFIF``C   C  7" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?OĚ Zizݖy dPI;I#ƣLogyV@s#lJOښG!פ)w4YyTgwѣq?|Ӝ}+,e-(n"{XK;1U$¾sm%vME|wG5;Mcn=aىoA:c/A佘c*x8kymHߜT~V>r9)2W|˝rڲa$vN^ߏɾ+hkg0ϖ69 JT.vmsEaWi%ݻE|ާ x"LW;9`OWs7>#|r'd w1HKD}:뱥 _</iE|O^/_^y̯Gk~^3z/?z,Ko ^ {i|\F oҶU^].JV{-HU^"=)}*sU#>?1"7ndެ|[χ|+^{Y q 1[ qV[1.'BK(QOz|kwgks%.g3$1pFOtjռt4M2dTOk!v7@3ȯz|4M}?fTUȓuw׷|ҼI;Y֯n#34plII5-|+=_R,B2gՑ쩸޾6𥭎 Weܢ۸H;JF6k_:Ugӡ#&KKcN29` aYͱVԝG/-wvonc 1E:/(yjvﯩt?R鷺Zԩ+d c}c!s+OFAkdK p`Q4SO4{HMҀX吝m*ð%#=WsZsDFTU$bﴀrMƴN[Sl:?Rժ$G_uݷ?'> DM4F >?p|i iz˼8M _i~_ӵ}#a &Mu4g3lN6ʂp*z}.1WCH2T9eZ*q}?U8j9[M2Z8K^mR8ixv?MK#-ڮ}#:˟Z汢MxNVekB Abt~#մu#ԑ:uաz69+vϟk:Eߋ+[ RqOuQ\GUԬP'9*%ȁ2k9"JA`?#\qf{:}Fj;L6E,'8ҟ]hB5m;ᆁoo>5u9"Y@i8bEqq|I'K/5cђ1mvfVQ@^Ez?]ox]?3oZj:_ zws<ڵ[y.Tc$ڦK-,WL]?HXLp<H褱];f|]CAiwc\Ln6sdgkk_m:Z6~L-∕[lۚ)}oU+>~I>`v明K؜t% \$^uIY-%D2@ ę qK[kOh VYⱖMSS(0#JR:\dMN/7 _Kx9 z[c0z^c77NOFԴC;]iR LK2J27|*mN{jGS2@PEFFGﶏ{M27WqX/.YN7BVUY31q^EV~|X+QYxγ"$߈&Y$T[= [;h1}6iKVv],]$G~(+S$mWoM5%?2_#Sq^hW/>`<(&RuQZQEQEQEQEQEQEQEِDd  s zA 8logoirc_miyK yK http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjKp_z5mqDLAhWGdj4KHaggDV4QjRwIBw&url=http%3A%2F%2Fwww.ibrance.com%2F&bvm=bv.115339255,d.cWw&psig=AFQjCNFCOdhd3y4WdZ8QJorHZKb7JKSDWg&ust=1456946538245224yX;H,]ą'c"`b)Tͽ󵮏5ڛl*snd)Tͽ󵮏5ڛPNG  IHDR1tEXtSoftwareAdobe ImageReadyqe<!iTXtXML:com.adobe.xmp 3IDATx\ յ}<,.@}`>!>B EDL\Р`P"*dql20[OoU?3}fA|}[Uw{{9jvGm{3^ot+y%EYvy9:d4AJ6UQFSX("NB?C0oeA ֎w4{ 3 %qDtq|7d%s!P}C}P߲0d^ASe/I,?ҕ{V,,muWٔj׉b۾Po{_8UmwG1PINܿe<-HJiWn|8KhXc#VNJg4 m"E|g}ki8<6S͕?QM eؔv}PO0•KHB^5[F D7V44+׷;Φ5BIO|ݟR(D nP8[VI"/y4s!nYtՀ'+>Aԩe~莩TZwVTmCu#>1~Q|XxGTs,wbf5Y2Чy)FT Sz>[P:0- B2D>PjoS*G{ }YP7׸˷0&v3%?1Ly7jAwPCtttQ8ٍ?C((6.­|=$K3](O8]Pv3f4t .]R ޤw^:boxam09"V/a݋A_)NoSՒDeWi19nK\&9ax3s)ϖ`Y}?%Ϲ$?H_el_ǑObx*$6:0䇡C[n\ӗǥ$t|2!)9i_{ '}Rm+y|̠D5!9KK3qEa<4!&,߃59-A!&2wk9nZMAX-!tF9ylEh|@:&G Zv~'TdڻC:R^JM?\RDjڋs8H֠ <=#E>Y!Pxqg)O@u_66:BAgve} `49l&p?w-wjFxVV̫&3`dTru7JG3[3Zىhi DIԵ)!9Rwr_#~+> [RĽ;CC;H[m*DtZ"H,U$AwK@4:w# {[I[CJ_K${q ؄{ Au_l~m18_H )ʹac"1O;ݤ­FyT)qT'h^hD/wk E4%ؖ'y2Ȭ%ZOe5{Y#đ݆ΥRS:Ƿ? }\֌ȴތxĸIJH̿x} &vVAV;e\vY~E:w5xR?>'UfCc1^$O0QO{/i(Mc($E?owHȒ#>Vnjt,V壘O OO&BNpL`S9^*lϠf'W G9|pn2574 +, \KTPf{['0qv}iz_K2n&vnDb!zN *(!t#CuX}>{PS_e$z|k\A%K8740D) Z_K@i} L`F/}׋^ *a1?@r0Ʉi[T|'6)*"] $iܦOn $|'"/@%WPAp% "2w ]8@ ?}/ DF#Kر3@R\HT<Egu5b3BCQ+gx& MCCLk&:#H)_\A>3Jhޮ6쇤:\A>!/z6Had<05+M@ Dd {ziB>yº`.b;)+@D@hQԠOg&U |- *(9 ' n31;bp< *_} ](=Ԡ%gTYD?5яitI%" m@C c|e îg3Xhub>"a?E*+㚦6l魛-ZSCm! ' w]64!?0Mt4Usub! Eԯ+3(\7s/_wE 0kVDx2-ޘ< 4.>hl!{~6;pN hħ *LX'Bޱ9m0 C'm~s f.=3'm>ջrP7q ,6͔FtV6mޕ m&.d= j3]OKAoSfķbBU_RӎdL*! l*E"8Niв1 >Nǒd{y/hj ijT;+G?Os,C湷4p>US9Š(g#F'02 bC#ٶCz|"K9!`͆@;٠[ۋ*b}NL41j=: GlGU=A8tI'V&ɫ>W2C@IoǸEv~?om$ċk5'ގ)\D?X;=W:›hA@YV L9=3n-;VM&.`C:=s(΍:AO00h_Eפ*;`6PQ٬IXgR3 Ll< {:!0L!tMg,C,aDQƤU40_Gnʰ?k-isf{y$Б=ҭx:>X޲ڿ'O@|b3M;46~9jl_iaRE!ēsa6mOHN xȠ;}ihw5r>7! 8rݩŭܰ8ʄF!%4n8=+u=3?C4!~&S}O>O:Y/I' yKIW'?-x@+<(-Y;GHh`"R/b&ѱn;7y6'ئoߜ(DI+Tp|ppD!7D@fz۶]16=30V3)Ua<ϊ}ٰs &o6 PM`=9jl\7i1 7ѹ 0Hkg;'.>FfP;6k],yUq gxk6+JSY.i}a+<+m Ux&kꇭ˪w; [6!bSpw'[ri̸y@f& l<>j@o[H;6_D%y#N2t) e7=>pDTO.W3vwF(ƭJ[fTĕǛuU;>Ո8 𤣜NDw~ X.#odtdF!=6 <@)# L*^Zw603H\+c 7ɜp%}L@Svo f%ioͦC2k?#9#-Y _ҍŌu= `\ @7@_=ssJ< yyXCE4'p Yn誵>rO޺YvdYڢv6:ψJǢ_@ˋ)$A+$y!0߷q}IfB`9asA4HK7cAn&5J5$TS$˹3sba{xx 02!2$Toyjx 쿥m-bI) L+Y<:2'](>i2fjl82fsgDff[I0'Y~\AہqSH"fL8>'QSd~|1HX) dltc1cBz,lEs&/!_Nf00"B㹕g3ĸ#6"W}D?E=aAlAC1xrx^@M~ 8cirFtܝ/npn`C_capasʹV&ۯ@ >mFGa&cSMb` .D>\e%yss^@3q؊Kd~-|"˹M#ϳʈ>[ںVh.Dѩe,'sAH<n6qO+CEq׹vYn>!0eyFI%$,nmp'uE#[DFqЭksG\֬Z~{ifdj}~g`X`bкk)ާWgif)p.Cq5ş]@uL8}'p{V#h#>ad^'--F~FU"$$F88B"\X"4u{xX|}tG&*۲:.UHB3:3'G?@v!'ϷsDd\#5&Z0>mCJwJW(B yK.psջCDDE/= a}qiZܩFg yJ xPh@ݙѫgpc WIqG0ԗn@':@/Zum@YFC~3Bhĩ\}&rP̺TET@]>eF::8]E:{t 5]D 9mDLw2<<8*y;͍?<݄ {p<Hv_>D6#S-AgZ^d/ZS/ j]߅ƃQ&)Zhf) zP,"mnN2ܓ/r.~"~!8-gøYse o_GUc̹ꐐ! B^mՑQpD'RAj쇸T@q Wa~:OM|k}LGx@•5&J̤ˑpzd.gd324ٮqS䫐o)q.¹Bև":RdC_ :VO"aҍ. IISĸY>1HnG!oHKxUQVXMFJ}LO(n9{+ @Z uK i-D%V\Hڴ|eճ [JR>DiE*ܻY+B+GB !V ͔i_Uգ)MdkUVҞǽ- g+L G.I㸀GzJZ/n]˜vy#{.=(Žo;8Pm1LFQIe"= VU B*gI+W ~t2­Uyq:HsU&Dzfa(Nj'snV9o =3*OWKuXAUA dUC7ڎofl[ 3J^e{-23֓*Pm؊ XA-ON8߶Q*nO{u>ireGhN"YGe=oգzGv2@ť=P^Afw0ԓ8f!n@,("Ω_m]{Ⱥ)Hތp%N*ުs۞ؾtN^c\h}w#Əy#D$]:Z3ɞ:kx2 ^X.F$d=Iό"" w62+n#2XJyٯfUYt뻃 n`O2TyY]p݊; !}3T:?lv6?p 18o=$iOGI`-} @d9"ADl eM% Dp7s/C@*1_& ^sőAև9E;j?p"l,Hzp;ބLaI}LRk3/޼z1'/zpZvP" <_7rԳv0|S0>p;- d sJ ꖝIENDB`;Dd QQ  A6?6 Image result for steglatroirc_miImage result for steglatroyK yK https://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjG4O-U09zYAhVqdt8KHbY1D9gQjRwIBw&url=https://www.steglatro.com/&psig=AOvVaw1UNqWsNpPLCe1V8YXfs1u6&ust=1516197818125707yX;H,]ą'c#" `b83TF0&o8hcsn83TF0&oPNG  IHDR{tEXtSoftwareAdobe ImageReadyqe<!iTXtXML:com.adobe.xmp ~+5IDATx] xE}#" x "x"끢""_EepU\oDPN9N2I$=Cofz_ׯW)NϤTSiGfTSɢP:-Je9T&:xФ)(bGݩtr<N%=P@?VwM5 l8Jo*=tvt#9e4iW/!~ҟTTӭ@% oFSRF8w\R~&ޖ>r!hҀq/Tke(ܞRu䨩W.))R`GcH0NT "QLEĔ)Y D\C*+,k&x@ u< >v*|m tҤ;qD̏=|;{[:,yl*PyUM pZy^+ @JIT&MSޞ;}縦Nj4@'v`TKtӔr'`o;i6_K ߜp}33??OwAM)x_E k51Q6x"+ Eq&=LiC|h|kͶjmRwwv"旒څ[v֋no\k͖)V\lU:ɇTn&) tM>w(vO׶mmOO]EEKֵ|,*DI#pFe,?u"g5a-̴rWWbst{V$NWP諕3gjҲw)4>Fj{ջ+.pkh6F_<#3?Z|tdfA^z 3uwT'8جf.#u^R0Je5H.آg\!Y^ O.FO`?Cļ\0+|͉-|>Tfde]_kboi BT'뮫O`o#bĚ; ifp7Š]eqݴHI7v)?aRHm)A㳣HP|0L!#)'#S 2tu 싳D]#"r=gG2Jڈ߰Tsu]"ź<mM{ZER "o]XS=r+n-}e|+Kf菨ISb דʅTM#kO_vx3{Ԏ2KK_~-92ielcFfRx@^+RT"bqVwe<ə3Wt2Kt'ꮬ)Pa%GCۈ4QF*焕aCE,5AGG3RX۝n+krC^,H܀{WLB QD@0`QPE2h{^cG& zM~/qƚivkS=W,АsoQ# w~K{${S @~S9֮ sHڿ^*]4pQT`$i_rL<7Tox5ʚw;(GQ| v&Mizp3:$[ΞET@O;>8ŔGIAo֮6Kl7Q9ARN. >E\m{\wcMAc0Aollwd RIl?5`̻ϴ2K,ݍ5xxf]"h263;N ߟK ;E :jeڽ}mr)a݅5y!;qeohw2k6H+[צvX'Q3u1{ G3Zٲ칿`I";Ri:m^vzy63q#Lӗj6[;{IM鯲;׌Hl+nWiWׂ?5'5%; 6k+ڶw7.b79  k2椦Oak4#+&oDsn ztHO/#mc#:)9k"B:3a u\7ٍv 7tlqWːb5K]2|,VPS3|Oa @_gZC4/0H`_iCJ)^Tf})ג(-uޗ5+}~%cy(ƣI7~$}QUD] =˕%é@="7+!΍}y->%, dG|>fzTU%(M{݇:Yŷh@A.}qj8 M1OVU~w#cK_vUrq x#D,q (D_|-D3ƭ &^H3/R3TAFmn*`G7xx*}H#0FpIS~[H~;T;iv7Z7ٱ1˧K`7H~C&!"p0Z(v?e;`mMxB_XH+k A69~#DlMӠ3lԀҠ2x9?Xy+)-7Hgl'bZ;Fq?z/QyWEo I>:Y  Pͨ||$γ3y(oZvR1h ]^Ң>>aNCEf4¥TJETR&niB~oghFxynLC/n }apte8^gW[GG~=@ùhyGD\yY9Ea'ͅ@}sy5bԒ/ޜ%7nA-F}aƎ:D$^j1fS >ׄ%T*z\nApM~H +>nP-ϑ5p! oAPDzytY+BgUYDmJ{.@$U3Nk BAB:up>e *(fz?zT"3%RM[Ävg60TKgj;;T;.wSU#-6JNw<@-"J`%1'=ײ~Ʈ4ر%Q>"̆p $b<;?[̪$?D~^i#l"K1af&p$~q`~՟Y[ILw8E3%=Mw (sNOeK3-:u']q`В 3V[cZߏ';otb^F+ V۝U턴 knytEާKC}K,u6~'aTx0.YI9"e+TS]rU/,OB!&j:e392-+#撰4fv_N&Q{ Ԏ~V`vhgJXOe;6A"J|jXlrmUo*bۧ]ˬ}KR"fNS1r٩R ]<TkXltX2l[;HF. A*B Cr$`pڔ-,RoXT7z<t:}n-BLQkl7_PP4@Nb@yy<9{셊:ftΌK8/Е?ja}#|wu+!ԀgfoC͵Җ NQyQ'̚}sHL*7. kgul}y&:z|fU CT,jTj'TC}"& gC B}8~^Cb#a:r|sꀷėlgu.HHmc?BIOT2"  :).α U#6dcVQT+~q1d>ª8o33O*QԳG2SE,-?T<[Vgb x۪ų[ј (Hn57"8I(&ykf<kwnǵRq?{9jǁO6h}($F"D\?ʢ@%zMG5q4c+7l1_ V^]j ~{~?_]"ĀʝxG߇r xe>Pfx e1CDT>9Trq6ψ}Ow"TzVBG +<]7a%tE;U jl;h}{!ckQqvh5;8Q/N O(JëWTXkT}z^Ox}6zOgXE ,҈L7 !nB:0!6UU]& G&x|pbQ&K\fխ.KлSe:>Fu~^/Mx^sXv5vKpV1LvIi7ڼRAz0'g 6o 1{"Gxq+:Y]R;?guƊUCޛ%W`7 N!eJga DbEx_гw٩`]1nSY$1I+6e3#GpЁ]GTcP zYC+,^2REhǃC6Ie]wlu"Ύ]`/H4E"9hB!<ڏHwFpYC|MCTR/-F "l|G]H ĄSYeBg|> vcұ%<;og9W4ca5?62Լ(_@̼j'<˶ A 8Ygzld]@_A>xѡ .N]hg =$"چe=#Dlrv$]wc|N=?_X!9V. R+ +&|^ڹ dYZyLw@! g0D '>@GQQ+mvBa$H셖  3&X˽B.tb  p}D9}%Zԧ@GX=3@d|)Jy yl$`sKkχ]~_%:+3ˍeRK^XZBHೌ6pf}g{0x6byFg<5NV3,01L#<=F{g<[ 7 FTfdHZV~K\l؂nՠ'ufdXT[0?CX;N|7q_u>%{ $_D̨nhI*r*'2]5/-.|xiVγ\8hiCA ϳ<E{hhkivbL,ܘFAy8 sAFLΚ'Nt=ceTx!sO>bd;e^t2>4K#%=z5{5iJ~Sc'bGVQzz+O9/tЅ~YŚ4 oa(*4OuŚ4oc5"b]Ɵ<$.dȩbw'.=gXT΅^Hms=DGl]Fo9rAFtߣjdYC;zœHEAO AF#v:a!a~jLrCgXزE,B-FM%nX?C%$?AYe-@0!{dzC#0#4ʃ $ )dATy@Kni+苺R-@?iNx'E?; z̀_icT"v"<զCO1s4U/o.2aWA$s[t/-hP=钧0S7Bf{*suHQ3Nasn[Dr|A[64zvY5ƪtzFH8u ҵ oY-2 <KmnށbPi6|K@`!a,XgmS\;Lg[%b.HHy > ?YTQ8WTl;Us.S +K!Q}c{ >^F$Sc1S" ]6khS6>!*R,y0:V628$a봡?+KX.փ볨m7䢚%'q |gTzIuQ~e[A8w|J9xqf3ߥkƝߠKo}9܁]|Lm'~?:ѬUA}{ޞн4 x|JB3tߝTFMg#m[{=iLN0r>$p]E໻|HN:bQQSŔw{ЋJUTJB§Yq8gDx̶c, 96CGz\,]ct8xhl߈ADdo *k [-0r T_P)p^KI~ov7RdVIfлT{,DB;?%Iek{+Ewf'%"3ˆ7!]*s "f10 T;PY}J3R&siIK5//bp1n8njNbӡgxץ ϳ< ^f:KQΛj^DEڅ zw7ª*L&~x&TY#e]xajf[fw C ʑb2Ng#n3j' ގe>9@wM@7L,{&M ^&M4iҀפI^&MNR.dcw'C]Ki' 3˄z̉Hg˷(7+.jWa v$"@#u/[\`Es/åca TyO|MqU R}Q=]r t׀O[d4Ȟ#Mae| (} 5WT-)߅AF D=d08=v&`FNĶ\5~-GBFǕ&=%}'бIZ$"Ty<#X@R'Rts%UXFAbcϽL:8$&$,0Z\C@<xKy +Mx<^iO`s3yq{EQ!sQ$*`@3{aɩ|RkbBZ&ZTz/*m,6Tq1AWRKViCNG6 Z b#h:4~zg(()ɢdΙ'*-|b:3^=k/A7QwbB{>ϓlqiP){|m?Qv[HjhGT&h>:3߃k !,Fg#(\)[^ͼτ !a8vdA(/dYCVwT!,+,[ 7 la*.Cmas>vd$efx f}zWSxD{ǝ:jEűe&ܭ8F$Nci$'p7cr=?u\E9k9V4ૡ㗘nNyKC$sރ<qz.pc606r{/mNՀ2ķ^BXxѐ:`umO5hK;X"0 xF1V0b]CB[ )/JMƲ$giSoNy^J@Ǡ1v켣g@Hh-"d@3zyP,JgR'V@k=J2i,&:΋D> ^-'guXʍ8"$0vr+aYq-{#p<ԯңRԀ*,3)gm5 &9ez55RێB?LQXb0_TG8WHTbRG4Õ shF[v=~1[CL:E/8V7!c׮RUTxUW@ cv%yIˉ WV46tSL=l6^K0/hdG7JNfq}*[x#C1w ?|<XvzuVlڂ ?~$ ˢʂoxp0vةT-sw?ᢍ΃~{( 舗gcnBty4Oo>|^ p3)bE0wdCgζ[$3El D,sq֭U燫5 rصVp+%ölw4q.uZ,UTiG)=AųicO4R)b;cv{;BN}۲ygÚ#.WWՇK.6an {/<`j)A΄X-ZT1pvGZԅ+;|BG:o=O ^σT5/LѩbzJVZc߇ER-GIϝh'C q5WYƟݱfNQD p<Ś7pGfzWMjJ<  A ?Ì& logoirc_mihttp://ra.xeljanz.com/sites/default/themes/custom/ra_xeljanz/logo.pngyK yK http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjq2rfBmaDLAhVLNj4KHekKBV4QjRwIBw&url=http://ra.xeljanz.com/&bvm=bv.115339255,d.cWw&psig=AFQjCNECqUX7Kv1whPyj61sR1ptpeMxm-Q&ust=1456946107167623yX;H,]ą'c#" `bp%69n\?zL%`snD%69n\?zPNG  IHDRTxtEXtSoftwareAdobe ImageReadyqe<"iTXtXML:com.adobe.xmp ր!IDATx] NU?2+3c7I*IʒJ-[d,Y#EeIl-RHo6 ={ygf>{9{緜9W *Etx%xC)6Ofy8DKF+"wH!AW )R$:wT޵߅/j8Q]%anlB$QΓ:JFp 7,TtA6t-$Lؤqy|_xxd)y?bw$Wa:$-s"Al#NǝGW%{@ QV/;o~:f#<5L d:"pAN[NQ`Ο6J Br$l~ݝgZ9t|p(fח4[יvHñFE/8$76qeWhSY:6*4tOU1bP7"mM)j(5$BJ*K؍kY1܎qK^P40UC N2j]*+9- ZJ}&1bPIH'ģsH6?@pn3BIBO'w:sG!%i~ܚS-S@A5X8JltEpWVRt{)3tkw5͇8i,S5w} Iwn1c;ԖgZY%)QGsO&@֗U87 )`=q裊274u}Uij0BPxdp ¯\dg;Gj*#[]M(9v P@PSmȱ/ '&1XoX4>z Mz'`VI Mt¬E!M!OM5,a꼎x½:Wq]:C:-t{9йevnPJ{4I:+jvcΝ~VsJ*LCd5AcfܿoVҞzkh>EΡXV'sPt]'q< P4?s~#?_w}ލС'~"b߉u"mbJ(Vؽ~:f |f9(٬wElCf)3&ˑ6J9xٍ?6qsċW<:qךBnxGiDCI I(#6p,Ns ؼO qN|EaB00>cMQ;Bߘ-(Yɀ)KzWU%ǧٚw6lS^&˖D-YUsHQGT9fQ4M/z3g9+~e +(]vxv,{~5_[}>b{5"Xvuqgo6]_HUL8cz:j?@+ˀ%֡ZSJ|PcETYTC𖣶&ﶧ~:迤J9 'QOnFY)}:2ᮘi7Qt!Svu٪]o6K&3:TB!Q|d`"ߎO+Ni⚡sDU`+۳::5>$KSmYA(^QMxc4gZq?v\h/1\C&0}ǁo"/ -UQS <DhR'NІBB^uxMhA wK,^1[vMcBGDDuAMm4jY-\(ƱB/zqR{GE>[Bk U#Kmu& :Q.=D8JRN4<5sS+m}+e88}'딋[/l9;+MJxsZsjY攝7yfȓwmĵ]if ~¶4Od9OR0rv֏b^5XNlKȭi&]7;ۃvdgZ`X .׃E^@XVjI\$vlq:dh G?4"YN&SG:=]/#3Ol+mIC hAGGu5/ qa%XN?H#pٴ4g\[ɵr\9g+fDW@x>{KQLWl(Tֳ)}XhgG3/9M6]ݫWO[C(zG=\S{DIwX$gm$?rAVagrN65uvȶ_X  z.sV.nO1k#5,HE}0`ql-{DlI6-Q89UđD*mB~Zu-*M*qas(~- P6^gAk9ԹDs7ӊ]0 cQ^uaCI4=uDv]JvnVw30IGTĵaGOOe&f@1-eAⱥJ:ͤc7]Kـ_]x](r e"^C#h(D"Uz$uicnQihTɤ_}V-Z7~-~Q!Jzʜ2X:!\؝G}naPΞw08ޘ;S̿-:V@IZ>XQǂ5yF^/+H0'Ҭz\ ~O&Y!KKe։&xӂk9{u=RmٹG+@Tdv)'ODZN>-$(-Ciě[Ǖ\G T3VHBCR>\OBb_OKnd.h^qwQƯ { -90%aT 8<;Wޜ臎px,T6=Zܰbup0sOVQ* I"$Yw#Jki!Y8TqQ؜ W&Nԛ?<>ADg#uҒu2&*@|Sg@!1m`(X<h:@4 ڃ}֜Ow%*I 6_E(cL 'n}!hH;29B*kHsعϬ;Lk9^-i}Ì i&́ȫJ:ndIE[g%&ߡ5 z׫BLdy?[hړy1, ޒȟC[ǭ*NPkim>ϳF`?֬p){! fߟHݨN/ˢ@&U&`dU<`{b}dSbBbPx(SN%Zbe+pj+`?#=8m&P|gu¶!_Z6[D\- .gRҭO 2Zd^1DXOomHkդ2򥋝h^998>r;fY z~61ݴ-stP)Wԁoc Ors@qWro0 2 2 2 R;~W\ίA, 汈%<|ʦR)b(Ck3(dzf>?yK^ř:@U9yb7=MA\ͽ_ Ms HBSi8zi*NsGm6'k"}gt&Mx|.mBp+l9\U=V̽08+% l_o)Z&b]&\ˤrŝ81- ;\Wߊ}̗w3qz֝}n?b*& RiM;yUi`w5wu<7L?yDap(FҤQcK1FܑVoO)J'.zR|Ze??MO)zM6m'ixPx] HLc>=;3-:W#.:c4?}"-#Xf{NCisUeI&ą3c]vsB"bL|&I])q?NԀpkv R\zhՈC#?Z{5*;ۨ*:7lRWS4i;oB>9Nwj QvNz[pzq_W޻၁[zk{+\׮!~xf#,5C"2nf\@<0N:.@Ldu\!Yv?,24!&G$+A NT!KәsM,Sz:W_¡u!zS{z~;fSR.8e՛0_U}:GIoBhnXMc#STD!iĠP,PGdg$|JrDY` JMPٓ>y)Ky}|`crAv'ڊњ!ŗV2Rsh֩_S[%j:o~𣟐5>ex3k,~+G :q>]CY7rRlFe4(EF ge\y,gv<2htI_or_/j_:dSp$oVD^sSdj{:% @Di{KVC2G )w}"h { i'1e7C\bc1j~g]W$!{6"s2c ?ھ|m>+j Yٮihĉ~ y!=+.J!T~b|vƞ&h]=qq/+vHXliFΫC. k/5|ih QGsFoin0Gŭvr>} K;,8\5dln9|N03 N2ԛ/.*Q2!lT(ÓJNs$帬3ǥﳤMX+ǣI.g0a1;O(hy =GgJ2EoQ3"cWkP𺟐nJ+BARoby˔.9AR$dAd{%]ĥ߇8'x~Cz4]#rZx5S8P哌<bt^l+mNHhVa JG[{N#MNމ>Z&[Ӟk.14ߴqEVu84@<"v+ф1ͼCs 87wxm6bPaNFdf&X wCde7&OB +|/y|y~+3)I|`P"s e !Z@E8Cȅ6C2P`H zuLWhs ZGn( J$ph*_|WK|Ѽ]GAr;ΜBM < cʓŵĠTCM%QQ&l(qp8ާh"ѷW hͻm=I;K<ʋqK{DEft*n]A׼rH`Z0#tl5t+^A">brE u4a2}5D{Tށ ~'3W (E=ߟxrqsN?k2貋k? iA$׿ 0ۢIENDB`^, 000002 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~_HmH nH sH tH D`D NormalCJOJQJ_HmH sH tH ^@^ " Heading 1$<@&"5CJ KH OJ PJQJ \^JaJ DA D Default Paragraph FontRiR 0 Table Normal4 l4a (k (0No List 4@4 Header!<O< ResumehOJQJ0O0 titled5:O": centered da$56U`16  Hyperlink >*B*phV^@BV 0 Normal (Web)dd[$\$OJ PJ QJ ^J aJFV`QF FollowedHyperlink >*B* phDoaD  textbold15CJOJ QJ \aJo(@oq@  textsmall1CJOJ QJ aJo(JOJ a3BA_Titledha$ CJ,OJQJDoD ggta1"5B*CJOJ QJ \aJo(ph333<@< }c List Paragraph^0a`0 }c0 HTML Cite6]<o< }c filesize1<CJaJ:o: }ccitation_year15\>o> }ccitation_volume16]xOx  MainTitle+$dx&& #$./0$a$CJOJPJQJ\^JaJtH\O\ Author" dP&& #$./CJKHOJQJtHpopBB_Author_Name! d] &5CJOJQJ_HmHnHsH tH uVo!V Heading 1 Char"5CJ KH OJ PJQJ \^JaJ f\@f $0z-Top of Form#$&dPa$<CJOJQJ^JaJToAT #0z-Top of Form Char<CJOJQJ^JaJBQB apple-converted-spacel]@l '0z-Bottom of Form&$$dNa$<CJOJQJ^JaJZoqZ &0z-Bottom of Form Char<CJOJQJ^JaJ4 @4 )1w0Footer(H$:o: (1w0 Footer Char CJOJQJH@H +E\ Balloon Text*CJOJQJ^JaJNoN *E\Balloon Text CharCJOJQJ^JaJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7fW+Ն7`g ȘJj|h(KD-dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJuV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbeSd̛\17 pa>SR!3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fvu"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK!ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э56?$Q,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-!ѐ' theme/theme/_rels/themeManager.xml.relsPK] mD $$                      K"c'879U<AG:KRTpVXZM\>_Qafhn(;>?ABCEFHKLNOQRTUVWXYZ\]^`ghj }n %O*|5&<BN@_hhp'<=@DGIJMPS[_afi<&=(=YHII KeKgKMNnNOO;PRQRrR>SV(WxWW(Xcijj0lplrlmXXXXXXXXXX%CCT # @H 0(  0(  B S  ?hit2_Hlt503856908_Hlt503856909_Hlt503856916_Hlt503856920cillEmEmm@@@@ciCmCmFmFmmhQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~<JXX<HHP a!a!y!!'"."4"4"<"q#q#y#$$$$$$s%s%{%&&&&&(((~)~)2*2*=****f+f+D,O,O,,,,P3P3A%A8BB7DHDoD?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgFT``FNVV w!!!!-"2":"B"B"x####$#$$$$$z%}%}% & &&&&((());*E*E****m+m+M,T,T,,,,T3T3A4ADBCFDXD|DEElEEEEFFFG#HVH-J>J'b'bbbdd;e;egg!j!j@k@km   !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgB\*urn:schemas-microsoft-com:office:smarttagscountry-region=g*urn:schemas-microsoft-com:office:smarttags PlaceName=h*urn:schemas-microsoft-com:office:smarttags PlaceType>"*urn:schemas-microsoft-com:office:smarttags PersonName9e*urn:schemas-microsoft-com:office:smarttagsplace8f*urn:schemas-microsoft-com:office:smarttagsCity9U*urn:schemas-microsoft-com:office:smarttagsState 0hgfehgfeghfe\ffe\feUfeUfef\ghfe\gehfehgfefeUfefeUfe\Uefe\fe\fef\efeU\e""e"""""""""""""""""e\\ee\e\e\\ee\(5*3/ 8 C P * 6 : B C J W ^ ` d %8E |&-nz_ h p | !!a!k!!!!!x""##N'X'(( ++++,,-- ....//&1.162=2h2r2222233333333333355556666%7.7S7^7d8h8j8n88899::E;K;<<>> >>8>G>>>>>d?v?????f@k@IAVAbAjAAAAA%B3B;BDBFBTBeBlBHEUEnEvEEEEEcFiFFFFF!G0GeGoGGGH H{JJKKKKKKKKLLpMyMMMMMMMeNnNOO2P;PPPPPPPVRaRW(WlXqXXXZZ[[aaub}bbbc cccccddeeeejfsfff1gGgHgWgTi[iNjWjjjjj^kckllllllllllllmmllm1;JPb$uy{I f pi&P!!E"P"$$%&u&&((b))**//////0$2'26222P3p34444O5l569666i7777d888 99 :::;:;;<<<==o>>'?????@AA BBBC7DDDcF{FrGGIJJKL#LnLLrNN?PmPQ#Q~RR#YYYYLZZN[[\\\\R]u]]^^^^N_r__!````aoaab>bbb~cc,eSeh*ikllllllllllllAmBmCmCmEmFmHmHmmmmmmmmmmmmmAM11JP$5Duy{IJf z /$2%2%2oRpRRR+W+W)X*X,X,XNXYcijklllllllmm: =12 :Bbp8KmP, "Ux4J$-& AxD,&$P2H=Jp#@EKKmL\FDTziVڬ:t %UHhh^h`.^`.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`56OJQJo(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`56OJQJo(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`.^`CJOJQJo(^`CJOJ QJ o(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(^`CJOJQJo(^`CJOJ QJ o(opp^p`CJOJQJo(@ @ ^@ `CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(^`CJOJQJo(PP^P`CJOJQJo(h^`OJQJo(hHh^`OJ QJ ^J o(hHohp^p`OJQJo(hHh@ ^@ `OJQJo(hHh^`OJ QJ ^J o(hHoh^`OJQJo(hHh^`OJQJo(hHh^`OJ QJ ^J o(hHohP^P`OJQJo(hH^`56OJQJo(.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`.^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.^`56OJQJo(^`.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.hh^h`.88^8`.L^`L.  ^ `.  ^ `.xLx^x`L.HH^H`.^`.L^`L.^`.^`.pL^p`L.@ ^@ `.^`.L^`L.^`.^`.PL^P`L.hh^h`.hh^h`56OJQJo(. ^`56o(.pLp^p`L.@ @ ^@ `.^`.L^`L.^`.^`.PLP^P`L.:t-&:#@%Ubp8=1EKFDT2H=AxD,P, ziLJ$LP>                  [        [                 [                                   Ts`        f!dQTQpAx~x g#$,KuBb~#10! "*7aVm 7Usp% ;{U iA* iA*>OIEIitZ766- $=`>,    ;iA*Let X!G)kiSiA*Ax>OIK}9}R7,K-,==Oi VEIv , X/zapi--J ,+gh`~K-Jx 88!Q> KKBb~#U+r$Vm  j%LZ("8(r(\4!*BOHiA*WjD+8pU+-/+#yKE+r$ KK766-ahbB.LZ(k2/B,KJ:4 vu,KtA7LZ(}R74!*,    88,9iA*,<!KX==`>E+Q>EG  y@J@!+A!,.Bp ;;BiUr,K/B+A,    bz>Fk21F;;BEG,<I=HBOH,.B KK=OI=H ,mO-iu>QdQTQ-,=(K,{`Qi$ixyS'Q~x:USBb~#D]T-WX= ,x*XiA*r(\gMo\LZ(K]-Wi7atZ KKVDe8(WWf{`Q sogLZ(ah XKWjG)k j% ,LkJ:4V4nJ@_ 2oLZ(.oU X/zap V ,8pJ@iUr*,    7UsmOKetLZ( vuyS,    KSvvi$ixK]K'Q~xWWf KK#yg# ;{u>Qh`~}9NJ@Za[FYe/W` eJ|9<FljB)-x)x\g"Oc#+*%3.%'J(^(A*&+z,,9p,|<-).;1j15x:6<;`@@B^B^BaB9CtFG+I7K4KDLRL?MhMT,=T[TzuV(6WYJ\O^v_a}cNc?eg'wgwgT iKi&kmoxo5p)q#qtsG)t1wyx2{R?{xE+6a9,i"P3qM8`Nr+vXt&#a3~$T0(V9/zNwBx5%T.\Bn<e5FYm~o>XxE\o,U6:uF_=nLq:fetR]tBS V. !BHMs^uR#W-@e[3ChtGh3[oll@$%&;<AB-F-G-gm@,.`@F@N@T@@UnknownG.[x Times New Roman5Symbol3. .Cx ArialMCentury Schoolbook5. .[`)Tahoma3.[x Times;. .Cx HelveticaoNewCenturySchlbkCentury SchoolbookGN#Mongolian Baiti7@CambriaI. ??Arial Unicode MS7. [ @Verdana?= .Cx Courier New;WingdingsA$BCambria Math"siiiC8t\ 78t\ 7!;20ulul 2q;HX  ?tF2!xx  resume1997 Pfizer IncCaron, StephaneL           Oh+'0X    ,8@HP resume1997 Pfizer Inc Normal.dotmCaron, Stephane2Microsoft Office Word@@~"@,-]W@,-]W 8t\՜.+,D՜.+,@ hp   Pfizer Inc7ul  resume1997 Title 8@ _PID_HLINKSAH`R2https://patents.justia.com/inventor/jade-d-nelson|http://www.micropat.com/perl/di/psrecord.pl?ticket=302269348856&listid=84128200606011547&container_id=323345&patnum=US7045652B2 hit3#hit3ydChttp://pubs.acs.org.proxy1.athensams.net/doi/abs/10.1021/jo502879mKihttps://scifinder.cas.org/scifinder/references/answers/D4FC6602X86F350ACX1EB2234131CE9C7DF7:D4FCF6EDX86F350ACX25691B7A1765EC6331/1.html?nav=eNpdkM8vA0EUx59tRIQDLiJCHByEZFZVt6QSqj9obLbSIuIio53UsruznZlWexEOOLg4KBcHBzfuxJ8gcRQuEnHnKnEy2xJhTi_v-51Pvu979QaNAhqwgP7YaCKa0OKx5TEtEQgOR6LLI0Ft3D8divhDWjAe1QIBv7SucQbtG7iEkYWdPEo6guQJ63g9v_jYPRhToCEJjSVsFUmZQduvzyjaa4TtX1V7Wo5fDhWAsgsAPglcF9AdWVyYTaVXk8ZS3FiQg5FanUmnFueTxoyAZtN2KROSwAuwDT75D-R203bTpPBvqzD6N980pRbBzn0f23k4-3yX-VZ-8rmen3PpH6Isj7KYI8qzmCFOWIkwlKM2Nh2UpbZNHZSRETIuyU4cXZ73nL7cKaDo0GpXUixnOtiaIxUBA7oEqRKk1kBqHaTWQWodpEpnWIcmu-IRuYAu3UurFoVpqbrpbJLcLObrGSLCZdeV4Tprx3gy-iM_WY8r1efBXq_Ln5Nrrm_9NrZXPbm5HvV5XW-1ynraJqeg9spfuEejiA&key=caplus_2013:1974382&title=Q29tbWVyY2lhbCBSb3V0ZSBSZXNlYXJjaCBhbmQgRGV2ZWxvcG1lbnQgZm9yIFNHTFQyIEluaGliaXRvciBDYW5kaWRhdGUgRXJ0dWdsaWZsb3ppbg&launchSrc=reflist&pageNum=1&sortKey=ACCESSION_NUMBER&sortOrder=DESCENDINGqjavascript:goFormView(%22/OrgSyn/orgsyn/orgsyn_form.asp?formgroup=quick_form_group&dbname=orgsyn&formmode=edit&unique_id=undefined&commit_type=undefined%22,%2217%22)KV .http://pubs.acs.org/doi/abs/10.1021/op300131eKW .http://pubs.acs.org/doi/abs/10.1021/op300130pg0/http://pubs.acs.org/doi/full/10.1021/jo902159zcor1H+http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6THR-4TS6SGY-D&_user=5844500&_coverDate=10%2F25%2F2008&_alid=853861992&_rdoc=1&_fmt=high&_orig=search&_cdi=5289&_sort=d&_docanchor=&view=c&_ct=10&_acct=C000000313&_version=1&_urlVersion=0&_userid=5844500&md5=ed6ffc8e92bd64b214363e6f4063f6d6Ahttp://pubs.acs.org/cgi-bin/article.cgi/joceah/2003/68/i10/html/jo034274rAF2nmhttps://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjxgvHTmqDLAhWLWj4KHbWeB2UQjRwIBw&url=https%3A%2F%2Fwww.bosulif.com%2F&bvm=bv.115339255,d.cWw&psig=AFQjCNE529cWN00tyIDnjvufSuHLOn1izQ&ust=1456946456785832}n http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjz5saemaDLAhXEVT4KHWnWCWkQjRwIBw&url=http://www.mainepersonalinjurylaw.com/2011/07/&bvm=bv.115339255,d.cWw&psig=AFQjCNH5y8MuyGY5DSgpyUM62atXUsFogg&ust=1456946060398627t}http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjKp_z5mqDLAhWGdj4KHaggDV4QjRwIBw&url=http%3A%2F%2Fwww.ibrance.com%2F&bvm=bv.115339255,d.cWw&psig=AFQjCNFCOdhd3y4WdZ8QJorHZKb7JKSDWg&ust=1456946538245224q&https://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwiDwuzWmaDLAhWHgj4KHYXnCGEQjRwIBw&url=https://www.pfizerpro.com/product/inlyta/rcc&bvm=bv.115339255,d.cWw&psig=AFQjCNG6wtR9dZXSJWCgFUz3gc2YBZQrvw&ust=1456946185266042`uhttps://www.google.com/url?sa=i&rct=j&q=&esrc=s&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjG4O-U09zYAhVqdt8KHbY1D9gQjRwIBw&url=https://www.steglatro.com/&psig=AOvVaw1UNqWsNpPLCe1V8YXfs1u6&ust=1516197818125707http://www.google.com/url?sa=i&rct=j&q=&esrc=s&frm=1&source=images&cd=&cad=rja&uact=8&ved=0ahUKEwjq2rfBmaDLAhVLNj4KHekKBV4QjRwIBw&url=http://ra.xeljanz.com/&bvm=bv.115339255,d.cWw&psig=AFQjCNECqUX7Kv1whPyj61sR1ptpeMxm-Q&ust=1456946107167623  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijkmnopqrstuvwxyz{|}~    !"#(),Root Entry F@4=7]W+Data l1Table`tWordDocument !SummaryInformation( DocumentSummaryInformation8MsoDataStore97]W<7]WETHDTWU5BGGM3==297]W<7]WItem  PropertiesUCompObj r   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q